Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: In vivo experiments and a case report

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 994-996

  Ishiguro, Tatsuaki ^a,b   Ishiguro, Ryumei ^a   Ishiguro, Miyu ^a   Iwai, Sayuri ^a  

^a Kamui Medical Co Ltd   (Japan)

^b Hibiya Uchisaiwaicho Clinic   (Japan)

Author keywords

Cholangiocarcinoma; Dichloroacetate omeprazole; Tamoxifen

Indexed keywords

CA 19-9 ANTIGEN; DICHLOROACETIC ACID; DIISOPROPYLAMINE DICHLOROACETATE; GEMCITABINE; LIVERALL; OMEPRAZOLE; SUPEROXIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CASE REPORT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; JAUNDICE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DICHLOROACETATE; DRUG SYNERGISM; FEMALE; FIBROSARCOMA; HUMANS; MIDDLE AGED; OMEPRAZOLE; TAMOXIFEN;

EID: 84861387195     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10507     Document Type: Article

References (16)

1. Warburg O: Ueber den stoffwechsel der tumoren. Constable, London 1930.
2. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 2008; 134(5):703-707.
3. Michelakis ED, Webster L and Mackey JR: Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99(7):989-994.
4. Plas DR, Thompson CB: Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 2002; 13:75-78.
5. Bonnet S, Archer SL, Allalunis-Turner J, et al.: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11:37-51.
6. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 2006; 38:1124-1144.
7. Luciani F, Spada M, Milito AD, et al.: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96(22):1702-1713.
8. Chen Y, Schindler M, Simon SM: A mechanism for tamoxifen-mediated inhibition of acidification. J Biol Chem 1999; 274(26):18364-18373.
9. Milito AD, Iessi E, Logozzi M, et al.: Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007; 67(11):5408-5417.
10. De Milito A, Canese R, Marino ML, et al.: pH-dependent anti-tumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010; 27(1):207-219.
11. Altan N, Chen Y, Schindler M, Simon SM: Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA 1999; 96(8):4432-4437.
12. Obrero M, Yu DV, Shapiro DJ: Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002; 277:45695-45703.
13. Michelakis ED, Sutendra G, Dromparis P, et al.: Metabolic modulation of glioblastoma with dichloroacetate. Sci Trasl Med 2010; 2(31):31-34.
14. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64(10):935-951.
15. White INH: Tamoxifen: is it safe? Comparison of activation and detoxification mechanisms in rodents and in humans. Curr Drug Metab 2003; 4(3):223-239.
16. Tonini G, Virzi V, Fratto ME, Vincenzi B, Santini D: Targeted therapy in biliary tract cancer: 2009 update. Future Oncol 2009; 5(10):1675-84.